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ABSTRACT  1 
Background: Medication administration errors may contribute to patient mortality, thus 2 
additional understanding of such incidents is required.  3 
Objectives: To analyse medication administration errors reported in acute care as resulting 4 
in death, to identify the drugs concerned, and to describe medication administration error 5 
characteristics (location of error, error type, patient’s age) by drug group.  6 
Methods: Medication administration errors reported in acute care in 2007 ̶ 2016 7 
(n=517,384) were obtained from the National Reporting and Learning System for England 8 
and Wales. Incidents reported as resulting in death (n=229) were analysed. Drugs were 9 
classified by two researchers using the British National Formulary. Drug categories were 10 
described by medication administration errors’ year, location, patient age, and error 11 
category based on the incidents’ original classification.  12 
Results: Errors were most often reported on wards (66.4%, n=152), and in patients aged 13 
over 75 years (41.5%, n=95). The most common error category was omitted medicine or 14 
ingredient (31.4%, n=72); most common drug groups were cardiovascular (20.1%, n=46) and 15 
nervous system (10.0%, n=23). Most errors in patients under 12 years concerned drugs to 16 
treat infection; cardiovascular drugs were most common among other age groups.  17 
Conclusions: In order to prevent these most serious of medication administration errors, 18 
interventions should focus on avoiding dose omissions, and administration of drugs for 19 
patient over 75 years old, as well as safe administration of parenteral anticoagulants and 20 
antibacterial drugs.  21 
 22 
Keywords: adverse event, death, drug, incident reporting, medication administration, 23 
patient safety 24 
Abbreviations 25 
ADE = adverse drug event 26 
BNF = British National Formulary 27 
ISMP = Institute for Safe Medication Practices  28 
MAE = medication administration error 29 
NHS = National Health Service 30 
NRLS = National Reporting & Learning System 31 
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INTRODUCTION 32 
In 2017, The World Health Organization (WHO) launched a third global patient safety 33 
challenge “Medication Without Harm”, aimed at improving medication safety, on the basis 34 
that medication errors are a leading cause of injury and avoidable harm in health care 35 
systems globally generating costs that has been estimated at 42 billion USD annually.¹ In 36 
February 2018, the report of the prevalence and burden of medication errors in England 37 
was published in response to the WHO challenge, estimating that 237 million medication 38 
errors at all stage of medication process occur in England per annum.² 39 
The United States National Coordinating Council for Medication Error Reporting and 40 
Prevention³ defines medication error as “any preventable event that may cause or lead to 41 
inappropriate medication use or patient harm while the medication is in the control of the 42 
health care professional, patient, or consumer”. The medication administration stage of the 43 
medication process is known to be prone to errors. Half or more of all medication incidents 44 
are medication administration errors (MAEs).² ⁴ ⁵ MAEs can be defined as “a deviation from 45 
the prescriber’s medication order as written on the patient’s chart, manufacturers’ 46 
preparation/administration instructions, or relevant institutional policies”.⁶ Direct 47 
observations of the inpatient medication process produce the most rigorous data on the 48 
prevalence of medication errors, and suggest that MAEs occur in 5% of non-intravenous and 49 
35% of intravenous doses⁷ or up to 20% of all doses given.⁸ ⁹ Fortunately, the majority of 50 
MAEs do not result in harm² ¹⁰, but some are serious or even fatal. An adverse drug event 51 
(ADE) is defined as “an injury resulting from medical intervention related to a drug".¹¹ 52 
Medication errors as well as ADEs during hospitalization are more likely in the presence of 53 
co-morbidity and polypharmacy,² ¹² and among older people.² ¹³ Some drugs are more likely 54 
to cause significant patient harm when used in error. These are listed as high-alert 55 
medications by the US Institute for Safe Medication Practices (ISMP).¹⁴ In acute care 56 
settings, these drug classes include anaesthetics, anti-arrhythmics, anti-thrombotics, 57 
chemotherapeutics, dialysis solutions, epidural or intrathecal medications, insulin, 58 
narcotics/opioids, and parenteral nutrition.¹⁴ The UK’s high risk drug list includes 59 
administration of methotrexate, diamorphine and morphine injections, low molecular 60 
weight heparins, anticoagulants, insulin, lithium, midazolam injection, opioids, injectable 61 
medicines, and liquid medicines as well as omitted doses.¹⁵ Additionally, a systematic review 62 
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revealed that 47 % of all serious medication errors were caused by seven drugs / drug 63 
classes. Those were methotrexate, warfarin, nonsteroidal anti-inflammatory drugs (NSAIDS), 64 
digoxin, opioids, acetylic salicylic acid, and beta-blockers.¹⁶   65 
Analysis of reported medication errors have traditionally included all medication incidents, 66 
whether or not they result in harm⁴ ⁵. By focussing on the most serious MAEs, the aim was 67 
to specifically study the characteristics of MAEs reported as resulting in patient death. This 68 
study’s objectives were 1) to analyse medication administration errors reported in acute 69 
care as resulting in death, 2) to identify the drugs concerned, 3) to describe MAE 70 
characteristics by drug group, and 4) to identify potential areas for intervention.   71 
 72 
METHODS 73 
Design & setting 74 
This was a retrospective study of MAEs reported to the National Reporting & Learning 75 
System (NRLS) for England and Wales. The NRLS collects national data on all patient safety 76 
incidents that are voluntarily and anonymously reported by staff employed in the National 77 
Health Services (NHS) and other health care organisations. Incidents (including near misses 78 
and incidents causing harm) can also be reported directly to the NRLS. Data reported for 79 
incidents include both categorical data (e.g. type, severity of incident) and a free text 80 
description of what happened. 81 
The original classification of the NRLS incidents were used. Based on this classification, 82 
location of error included: ward, intensive care unit, operating theatre, recovery room, 83 
anaesthetic room, therapy department, pharmacy, mortuary, hospital buildings, other, or 84 
the information was missing. Types of errors were: omitted medicine / ingredient, wrong / 85 
unclear dose or strength, wrong drug / medicine, wrong frequency, wrong quantity, wrong 86 
route, adverse drug reaction (when used as intended), patient allergic to treatment, contra-87 
indication to the use of the medicine in relation to drugs or conditions, mismatching 88 
between patient and medicine, wrong storage, wrong method of preparation / supply, 89 
wrong / omitted verbal patient directions, wrong / omitted / passed expiry date, other, or 90 
unknown.  91 
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 92 
 93 
Data acquisition 94 
A data sharing agreement was signed after applying and receiving acceptance from NRLS for 95 
data access. NRLS extracted the data (medication administration errors reported to the 96 
NRLS between 1 January 2007 and 31 December 2016) in December 2017. Inclusion criteria 97 
were that the incident was documented as involving: 1) medication, 2) administration / 98 
supply of a medicine from a clinical area, and 3) acute NHS trust (either a specialist or non-99 
specialist organisation). Of all incidents (n=517,384), 94.3% concerned an acute non-100 
specialist Trust, and only 5.7% acute specialist Trust. The total number of incidents extracted 101 
was 517,384. Of these, only MAEs reported as resulting in death caused by a patient safety 102 
incident (n=229, 0.04%) were analysed. Only the categorical data fields within the NRLS data 103 
were acquired. 104 
 105 
Data analysis 106 
Descriptive statistics of the data (n=229 MAEs reported as resulting in death)  were 107 
calculated using IBM SPSS (version 23.0). Characteristics of the data were described using 108 
frequencies and percentages, and relationships amongst factors explored via cross-109 
tabulation. Reports including the name of the drug were classified using the British National 110 
Formulary (BNF) classification.¹⁷ The BNF classification’s main groups are divided under the 111 
following sections: 1. Gastro-intestinal system, 2. Cardiovascular system, 3. Respiratory 112 
system, 4. Nervous system, 5. Infection, 6. Endocrine system, 7. Genito-urinary system, 8. 113 
Malignant disease, 9. Blood and nutrition, 10. Musculoskeletal system, 11. Eye, 12. Ear, 114 
nose, and oropharynx, 13. Skin, 14. Vaccines, 15. Anaesthesia, and 16. Emergency treatment 115 
of poisoning. MH classified the drugs into BNF groups which were then verified by BDF. Drug 116 
categories were cross-tabulated by MAEs’ year, location, patients’ age, and error category. 117 
The age bands used within the NRLS were amalgamated into six broader groups: 1) under 12 118 
years, 2) 12-17 years, 3) 18-25 years, 4) 26-55 years, 5) 56-75 years, and 6) over 75 years. 119 
 120 
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 122 
Ethics 123 
King’s College London ethics committee approved the study (LRS-17/18-5150). The data did 124 
not include any personal or organisational identifiers, thus anonymity of the reporters, 125 
patients, other involved persons, and organisations could be guaranteed.  126 
 127 
RESULTS 128 
Characteristics of MAEs resulting in death 129 
MAEs resulting in death (n=229) occurred most often in 2008 (n=28, 12.2% of all MAEs 130 
reported as causing death) and 2016 (n=28, 12.2%), and less often 2012 (n=13, 5.7%). 131 
Overall 66.4% of MAEs were reported as occurring on non-critical care wards, and 41.5% 132 
(n=95) occurred amongst patients aged over 75 years. The most common error category 133 
was omitted medicine or ingredient (n=72, 31.4%). (Table 1.) 134 
 135 
Drugs related to MAEs 136 
The name of the related drug was mentioned in 58.1% (n=133) of all MAEs. The most 137 
common group of drugs in MAEs reported as resulting in death were cardiovascular drugs 138 
(20.1%, n=46). Of these 26 involved parenteral anticoagulants, six oral anticoagulants, and 139 
six sympathomimetics. The second most common were drugs of the central nervous system 140 
(10.0%, n=23). Of those, analgesics (n=10) were most common. Other common drug groups 141 
were antibacterials (n=20), cytotoxic drugs (n=8), and insulin (n=7). (Tables 2.) More specific 142 
information by name of drugs concerned (as written in the reports) is presented in Table 3.  143 
 144 
MAE characteristics by drug groups 145 
MAEs reported as resulting in death in general ward areas were most often reported for 146 
cardiovascular drugs (34 cases of 152 incidents at ward) followed by nervous systems drugs 147 
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(19 of 152). MAEs occurring in intensive care units most commonly concerned drugs used in 148 
blood and nutrition (4 of 18 incidents in intensive care units) and infection (3 of 18). Most 149 
MAEs in patients under 12 years were drugs to treat infection (3 of 10 incidents in patients 150 
under 12 years) whereas for patient’s aged 26-55 years cardiovascular drugs (6 of 29 151 
incidents in patients aged 26-55 years) were the most common. Cardiovascular drugs (9 of 152 
58 of incidents in patients aged 56-75) or drugs to treat infection (10 of 58) featured most 153 
often for patients aged 56-75, and cardiovascular drugs (23 of 95 incidents in patients aged 154 
over 75 years) and nervous system drugs (11 of 95) for patients aged over 75. (Online 155 
appendix.) 156 
The most common error categories for cardiovascular drugs were omitted medicine / 157 
ingredients (18 of 46 incidents with cardiovascular drugs), followed by wrong / unclear dose 158 
or strength (6 of 46). For nervous system drugs the most commonly reported errors were 159 
wrong / unclear dose or strength (4 of 23 incidents with nervous system drugs), wrong 160 
quantity (3 of 23), and wrong drug / medicine (3 of 23). For drugs to treat infection the most 161 
commonly reported errors were omitted medicine /ingredient (5 of 21 incidents with drugs 162 
to treat infection), adverse drug reaction (4 of 21), and patient allergic to treatment (4 of 163 
21). (Online appendix.) 164 
 165 
DISCUSSION 166 
In this study, MAEs most commonly reported as causing mortality in acute cate Trusts over 167 
the 10-year period 2007 to 2016 were omissions of drugs. They occurred more often on 168 
hospital wards than other locations and amongst patients aged over 75 years. The drugs 169 
most commonly involved were parenteral anticoagulants followed by antibacterial drugs. 170 
Interventions to reduce MAEs, should therefore focus on those areas.  171 
Almost one third of MAEs were related to omissions of drug doses. A previous study 172 
analysing all medication errors reported to the NRLS between 2005 and 2010 also found 173 
that omissions were the most commonly reported type, accounting for around 15% of 174 
incidents,⁴ which is much lower than in the present study. In addition, a previous systematic 175 
review using observational evidence demonstrated that omission errors are the most 176 
common MAE type internationally.¹⁸ More attention is needed on omissions since the 177 
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consequences can be serious. The risks of delay or omission of drugs have been categorised 178 
by the English National Patient safety Agency (NPSA),¹⁹ which suggests that omission of 179 
anticoagulants, insulins, and cytotoxic agents, as identified in this study, can cause 180 
significant or catastrophic long-term patient impact. Reasons for medication omissions are 181 
manifold, such as staff shortages and delays in medication dispensing,²⁰ patients' inability to 182 
take the medicine, or medication unavailability.²¹ More active solutions for problems related 183 
to medication omissions should be implemented with the development of technology, 184 
improving work processes, flow of information, verification systems and availability of 185 
drugs. Still, it is challenging to recommend any specific interventions, as a previous 186 
systematic review and meta-analysis demonstrated that interventions developed to 187 
decrease MAEs, including nurse training and education, automated delivery systems and 188 
barcode-assisted medication administration systems, did not find clear effect of the 189 
interventions.²² 190 
Cardiovascular drugs, particularly parenteral anticoagulants, were the most common drug 191 
group involved in MAEs reported as resulting in death. Many of those were omitted or 192 
administered in the wrong dose, strength, frequency, or quantity. Cardiovascular drugs 193 
were associated with the highest median proportion of preventable adverse drug reactions 194 
(PADR) also in a previous review of systematic reviews of inpatients’ PADRs²³. Those were 195 
also found to be the most frequent types of drugs involved in preventable ADEs²⁴, and 196 
commonly related to observed MAEs ¹⁸.  Similarly, heparin and low molecular weight 197 
heparin were amongst the most common drugs reported as causing death in other previous 198 
studies,⁴ ⁵ demonstrating that the consequences of an error are more devastating for 199 
patients receiving these types of drugs as there is only a narrow difference between an 200 
effective and a toxic dose.⁵ In addition, omission of such drugs may have a significant or 201 
catastrophic long-term impact¹⁹ and the risk of ADEs has ben found to increase especially for 202 
inpatients with coronary disease and using related drugs.¹² Thus, efforts to avoid dose 203 
omissions should focus on these patients.  204 
Antibacterial drugs were also a common group of drugs identified in the present study. 205 
Most MAEs related to these drugs were omissions, adverse drug reactions, and 206 
administration to patients with a documented allergy. These drugs have been previously 207 
found to be related to medication errors causing death,⁴ but are not amongst ISMP's list of 208 
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high-alert medications.¹⁴ The data in the present study show that patients’ allergies and 209 
other adverse reactions of drugs may not be verified as carefully as required. Other 210 
common drugs related to patients’ deaths were opioids, insulins, and cytotoxic drugs, all in 211 
ISMP's list of high-alert medications¹⁴. The most common error types for nervous systems 212 
drugs (including opioids) were wrong or unclear dose or strength, wrong drug, or wrong 213 
quantity. Further research is needed to understand the reasons for these error types.  214 
Each death caused by medication error is one death too many. There should also be some 215 
focus on rare and unusual MAEs. For example two MAEs resulting in death were caused by 216 
the administration of potassium permanganate (orally instead of topically). An NPSA Patient 217 
Safety Alert produced in 2014 was based on death caused by a patient ingesting potassium 218 
permanganate.²⁵ One incident in our data occurred before this alert and another 219 
afterwards, in 2016. More knowledge and competence in handling drugs and administration 220 
of drugs should be provided to all health professionals, especially nurses, as they are usually 221 
the final step in the medication use process. Educating patients about the medications they 222 
are receiving may help to reduce MAEs.  223 
 224 
Strengths and limitations 225 
This study was of a sufficient size to be able to identify rare MAEs that result in death. Drugs 226 
were classified into BNF category by two researchers, which supports reliability and validity. 227 
It is known that reported incidents do not represent all those that occur, and it is assumed 228 
that self-reporting systems (such as the NRLS) detect only a very small proportion of all 229 
medication incidents². The incident reporting system has further possible weaknesses in 230 
that reporters may evaluate the consequences of incidents incorrectly such that some of the 231 
MAEs reported as resulting in death incidents may allude to possible rather than actual 232 
consequences. It was only possible to identify the name of the drug for 56% of all reports 233 
and only the categorical fields from the NRLS data were used in this analysis. In addition, the 234 
original classification of NRLS incidents was used, and it is thus impossible to evaluate what 235 
error types are hidden under the ‘other’ category. A further issue is whether an ‘adverse 236 
drug reaction’ may be an MAE when medication is administered for the first time to the 237 
patient, but descriptions of reported incidents did not include enough information to allow 238 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
9 
 
re-classification. The free text descriptions could have provided a more detailed 239 
understanding of each incidents and further information about the drugs involved. 240 
 241 
 242 
 243 
CONCLUSION  244 
In order to prevent the most serious MAEs, additional studies and interventions should 245 
focus on dose omissions and administration of drugs to patients over 75 years old, as well as 246 
safe administration of parenteral anticoagulants and antibacterial drugs. Checking patient 247 
allergies and undertaking required verification procedures before medication 248 
administration, as well as additional education for safe handling and administration of drugs 249 
should be mandatory. Additional studies using observational research methods are 250 
important for exploring further the dynamics of serious MAEs.  251 
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Table 1. Characteristics of medication administration incidents resulting in death (n=229) 347 
Variable No. % 
Year 
- 2007 
- 2008 
- 2009 
- 2010 
- 2011 
- 2012 
- 2013 
- 2014 
- 2015 
- 2016 
 
23 
28 
19 
22 
26 
13 
25 
24 
21 
28 
 
10.0 
12.2 
8.3 
9.6 
11.4 
5.7 
10.9 
10.5 
9.2 
12.2 
Location 
- Ward 
- Intensive care unit / high dependency unit 
- Operating theatre 
- Other 
- Recovery room 
- Hospital buildings (inside) 
- Therapy department 
- Pharmacy 
- Anaesthetic room 
- Mortuary 
- Missing information 
 
152 
18 
10 
4 
2 
2 
2 
1 
1 
1 
36 
 
66.4 
7.9 
4.4 
1.7 
0.9 
0.9 
0.9 
0.4 
0.4 
0.4 
15.7 
Patient’s age 
- under 12  
- 12-17 
- 18-25 
- 26-55 
- 56-75 
- over 75 
- Missing 
 
10 
0 
2 
29 
58 
95 
35 
 
4.4 
0.0 
0.9 
12.7 
25.3 
41.5 
15.2 
Medication error category 
- Omitted medicine / ingredient 
- Other 
- Wrong / unclear dose or strength 
- Adverse drug reaction (when used as intended) 
- Wrong drug / medicine 
- Wrong frequency 
- Wrong quantity 
- Wrong route 
- Patient allergic to treatment 
- Contra-indication to the use of the medicine in relation to drugs or 
conditions 
- Mismatching between patient and medicine 
- Unknown 
- Wrong storage 
- Wrong method of preparation / supply 
- Wrong / omitted verbal patient directions 
- Wrong / omitted / passed expiry date 
 
72 
37 
24 
21 
16 
13 
13 
8 
7 
5 
 
3 
3 
2 
2 
2 
1 
 
31.4 
16.2 
10.5 
9.2 
7.0 
5.6 
5.6 
3.5 
3.1 
2.2 
 
1.3 
1.3 
0.9 
0.9 
0.9 
0.4 
 348 
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Table 2. Classified drugs related to death causing medication administration incidents 350 
(n=229) 351 
BNF Drug classes No. % 
1. Gastro-intestinal system 0 0.0  
2. Cardiovascular system 
- 2.2 (n=1) Diuretics 
- 2.3 (n=2) Anti-Arrhythmic Drugs 
- 2.5 (n=2) Hypertension and Heart Failure 
- 2.7 (n=6) Sympathomimetic 
- 2.8 (n=26) Parenteral Anticoagulants, (n=6) Oral Anticoagulants 
- 2.10 (n=1) Stable Angina, Acute/Coronary Synd&Fibrin 
- 2.11 (n=2) Antifibrinolytic Drugs & Haemostatics 
46 20.1 
3. Respiratory system 
- 3.6 (n=2) Oxygen 
2 0.9 
4. Nervous system  
- 4.1 (n=3) Hypnotics And Anxiolytics 
- 4.2 (n=1) Drugs Used In Psychoses & Rel.Disorders 
- 4.3 (n=1) Antidepressant Drugs 
- 4.6 (n=1) Drugs Used In Nausea And Vertigo 
- 4.7 (n=10) Analgesics 
- 4.8 (n=6) Antiepileptic Drugs 
- 4.9 (n=1) Drugs Used In Parkinsonism/Related Disorders 
23 10.0 
5. Infection 
- 5.1 (n=20) Antibacterial Drugs 
- 5.3 (n=1) Antiviral Drugs 
21 9.2 
6. Endocrine system 
- 6.1.1 (n=7) Insulin 
- 6.3 (n=1) Corticosteroids (Endocrine) 
8 3.5 
7. Genito-urinary system 0 0.0 
8. Malignant disease 
- 8.1 (n=8) Cytotoxic Drugs 
- 8.2 (n=1) Drugs Affecting The Immune Response 
9 3.9 
9. Blood and nutrition 
- 9.1 (n=1) Anaemias + Other Blood Disorders 
- 9.2 (n=4) Fluids And Electrolytes 
- 9.3 (n=2) Intravenous Nutrition 
- 9.5 (n=4) Minerals 
11 4.8 
10. Musculoskeletal system 
- 10.2 (n=1) Drugs Used In Neuromuscular Disorders 
1 0.4 
11. Eye 
- 11.8 (n=1) Miscellaneous Ophthalmic Preparations 
1 0.4 
12. Ear, nose, and oropharynx 0 0.0 
13. Skin 
- 13.11 (n=3) Skin Cleansers, Antiseptics & Desloughing 
3 1.3 
14. Vaccines 0 0.0 
15. Anaesthesia 
- 15.1 (n=1) General Anaesthesia 
1 0.4 
16. Emergency treatment of poisoning 2 0.9 
Multiple 2  0.9 
Other 3 1.3 
Missing  96 41.9 
Total  229 100 
 352 
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Table 3. Names of the drugs related to death causing incidents (as written in reports)  
BNF code Drug names (as written in incident reports)  
2. Cardiovascular system  
2.2 Diuretics bumetanide 
2.3 Anti-Arrhythmic Drugs Digoxin [digitalis], amiodarone 
2.5 Hypertension and Heart 
Failure 
doxazosin and ramipril, verapamil 
2.7 Sympathomimetic noradrenaline x6, adrenaline x2, isoprenaline, metaraminol 
2.8 Parenteral Anticoagulants & 
Oral Anticoagulants 
enoxaparin x 7, Clexane [enoxaparin] x 6, heparin x 6, tinazaparin x 3, 
Fragmin [dalteparin sodium] x 4, warfarin x 3, rivaroxiban x 2, apixaban 
2.10 Stable Angina, Acute/Crnry 
Synd&Fibrin 
alteplase 
2.11 Antifibrinolytic Drugs & 
Haemostatics 
factor VIII, vitamin K 
3. Respiratory system  
3.6 Oxygen oxygen x 2 
4. Nervous system  
4.1 Hypnotics And Anxiolytics midazolam x 2, lorazepam 
4.2 Drugs Used In Psychoses & 
Rel.Disorders 
haloperidol 
4.3 Antidepressant Drugs mirtazapine 
4.6 Drugs in Nausea And Vertigo prochlorperazine / cyclizine, 
4.7 Analgesics aspirin, oxycodene x 3, fentanyl, remifentanil, morphine x 2, 
diamorphine, buprenorphine 
4.8 Antiepileptic Drugs phenytoin x 4, phenobarbital, thiopentone 
4.9 Park'ism/Related Disorders co-careldopa 
5. Infection  
5.1 Antibacterial Drugs co-amoxiclav x 4, gentamicin x 3, Augmentin [amoxicillin and clavulanate] 
x 3, Tazocin [piperacillin sodium /tazobactam sodium] x 2, cefuroxime, 
flucloxicillin x2, daptomycin, benzylpenicillin, rifampicin, trimethoprim, 
levofloxacin, linezolid 
5.3 Antiviral Drugs abacavir 
6. Endocrine system  
6.1.1 Insulin insulin x 7 
6.3 Corticosteroids (Endocrine) hydrocortisone 
8. Malignant disease  
8.1 Cytotoxic Drugs chemotherapy x 2, cyclophosphamide x 2, eribulin, vinorelbine, 
ifosfamide, bleomycin 
8.2  Immune Response Drugs alemtuzumab 
9. Blood and nutrition  
9.1 Anaemias + Blood Disorders iron dextran 
9.2 Fluids And Electrolytes potassium chloride x2, 0.9% normal saline 1000ml, sando K 
9.3 Intravenous Nutrition glucose, Vamin [amino acids] 
9.5 Minerals magnesium x2, calcium chloride x 2 
10. Musculoskeletal system  
10.2 Drugs In Neuromusc. Disord. pyridostigmine   
11. Eye / Miscellaneous 
Ophthalmic Preparations 
fluorescein 
13. Skin  
13.11 Clean., Antisep. & 
Desloughing 
chlorhexidine, potassium permanganate 
15. Anaesthesia  
15.1 General Anaesthesia atropine 
16. Emerg. treatment of 
poisoning 
flumazenil, protamine sulphate 
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Online appendix. Medication administration incidents (n=229) characteristics by drug groups 
BNF Drug classes 
 
 
Charecteristics 
2. Cardio-
vascular 
system  
3.      
Respi-
ratory 
system  
4. 
Nervous 
system  
5. 
Infec-
tion  
6. 
Endocrine 
system  
8. 
Malignant 
disease  
9.  
Blood and 
nutrition  
10.  
Musculo-
skeletal  
system  
11.  
Eye 
13. 
Skin  
15.  
Anaest-
hesia  
 
16.  
Emergency 
treatment  
Missing / 
other / 
multiple 
TOTAL 
Incidents’ location               
Ward 34 1 19 11 6 5 5 1 0 2 1 2 65 152 
Intensive care unit  3 0 1 3 1 0 4 0 0 0 0 0 6 18 
Operating theatre 0 0 1 2 0 0 0 0 0 1 0 0 6 10 
Other 2 0 0 1 0 0 0 0 0 0 0 0 1 4 
Recovery room 0 0 1 0 0 0 0 0 0 0 0 0 1 2 
Hospital buildings  0 0 0 0 0 2 0 0 0 0 0 0 0 2 
Therapy depart. 0 0 0 0 0 0 0 0 0 0 0 0 2 2 
Pharmacy 0 0 0 0 0 0 0 0 0 0 0 0 1 1 
Anaesthetic room 0 0 0 0 0 0 0 0 0 0 0 0 1 1 
Mortuary 1 0 0 0 0 0 0 0 0 0 0 0 0 1 
Missing 6 1 1 4 1 2 2 0 1 0 0 0 18 36 
TOTAL 46 2 23 21 8 9 11 1 1 3 1 2 101 229 
Patient’s age               
under 12 2 0 1 3 0 0 2 0 0 0 0 0 2 10 
18-25 0 0 1 0 0 0 0 0 0 0 0 0 1 2 
26-55 6 0 3 1 0 2 1 0 0 0 0 1 15 29 
56-75 9 1 3 10 0 5 4 0 0 1 1 0 24 58 
over 75 23 1 11 4 5 1 3 1 0 2 0 1 43 95 
Missing 6 0 4 3 3 1 1 0 1 0 0 0 16 35 
TOTAL 46 2 23 21 8 9 11 1 1 3 1 2 101 229 
Error Category               
Omitted medicine / 
ingredient 
18 0 2 5 2 1 5 1 0 0 0 1 37 72 
Other 4 0 2 0 3 2 1 0 0 0 1 1 23 37 
Wrong / unclear 
dose or strength 
6 1 4 0 1 2 2 0 0 0 0 0 8 24 
Adverse drug 
reaction (when 
used as intended) 
2 0 1 4 0 1 1 0 1 1 0 0 10 21 
Wrong drug / 
medicine 
4 0 3 1 1 0 0 0 0 0 0 0 7 16 
Wrong frequency 3 0 1 1 0 1 1 0 0 0 0 0 6 13 
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Wrong quantity 4 1 3 1 0 0 1 0 0 0 0 0 3 13 
Wrong route 2 0 1 0 0 1 0 0 0 2 0 0 2 8 
Patient allergic to 
treatment 
0 0 0 4 0 0 0 0 0 0 0 0 3 7 
Contra-indication .. 1 0 1 2 0 1 0 0 0 0 0 0 0 5 
Mismatching  1 0 1 1 0 0 0 0 0 0 0 0 0 3 
Unknown 0 0 3 0 0 0 0 0 0 0 0 0 0 3 
Wrong storage 0 0 0 1 0 0 0 0 0 0 0 0 1 2 
Wrong preparation  0 0 0 0 1 0 0 0 0 0 0 0 1 2 
Wrong verbal 
patient directions 
0 0 1 1 0 0 0 0 0 0 0 0 0 2 
Wrong / omitted / 
passed expiry date 
1 0 0 0 0 0 0 0 0 0 0 0 0 1 
TOTAL 46 2 23 21 8 9 11 1 1 3 1 2 101 229 
 
 
